Interface Biologics Receives ISO 13485:2003 Certification
Toronto, Canada, October 26, 2010 – For Immediate Release
Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, today announced that it received ISO 13485:2003 certification.
“We are proud to have completed and attained ISO 13485 certification for the design and manufacturing of our medical polymers”, said Thomas P. Reeves, President and CEO. “Achieving certification to ISO 13485:2003 illustrates IBI’s commitment to quality for our customers, partners, and for the patients and healthcare providers who will rely on medical devices that incorporate our anti-thrombogenic, anti-infective and programmable therapeutic delivery technologies.”
ISO 13485:2003 is the quality management system standard specific to the medical industry. The requirements emphasize critical areas impacting design, process, quality and manufacturing reliability for medical device products. This certification is an internationally recognized management system standard developed by the International Organization for Standardization (ISO).
“A growing number of device manufacturers are demanding that their suppliers have validated and compatible quality systems and processes”, adds Dr. Art Rosenthal, a member of the Board of Directors at IBI. “Certification to ISO 13485:2003 highlights IBI’s ability to design and manufacture medical device products that consistently meet customer and regulatory requirements.”
About Interface Biologics Inc.
Interface Biologics is an early commercial stage privately held company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic devices that reduce thrombosis without the need for heparin, anti-infective polymers, and programmable combination drug delivery devices. IBI, a University of Toronto spinoff, is now located at the MaRS Centre in Toronto, Canada. For more information about Interface Biologics, please visit interfacebiologics.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Julie Fotheringham - Partner, Hageman Communications